Showing clear confidence that its investigational mu-opioid agonist, NKTR-181, will gain FDA approval this summer, Nektar Therapeutics Inc. is talking up a recently established subsidiary poised to launch and market the chronic back pain drug. The new entity, Inheris Biopharma Inc., "will lead all of the preparations for the potential commercialization of NKTR-181, as well as development of other CNS programs, enabling Nektar to remain focused on advancing our immuno-oncology and immunology development pipeline," said Howard Robin, Nektar's president and CEO.